Systemically administered alcadein peptide p3-Alcβ neutralizes brain Alzheimer's Aβ oligomers

Sam Gandy

doi:10.1016/j.molmed.2023.04.007

Systemically administered alcadein peptide p3-Alcβ neutralizes brain Alzheimer's Aβ oligomers

Sam Gandy

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

Alcadeins are among the 90 known substrates for γ-secretase, the aspartyl proteinase complex that liberates the amyloid β (Aβ) peptide by intramembranous cleavage of the ß-carboxy terminal fragment of the Alzheimer's amyloid precursor protein (APP). A new study by Hata et al. provides some surprising results regarding a potential role for alcadeins and their fragments in the prevention and/or treatment of the dementia of Alzheimer's disease (AD).

Original language	English
Pages (from-to)	487-488
Number of pages	2
Journal	Trends in Molecular Medicine
Volume	29
Issue number	7
DOIs	https://doi.org/10.1016/j.molmed.2023.04.007
State	Published - Jul 2023

Keywords

Alzheimer's disease
alcadein
amyloid
oligomer
positron emission tomography

Access to Document

10.1016/j.molmed.2023.04.007

Cite this

@article{19ad3401407b4428938567c23be83f8d,

title = "Systemically administered alcadein peptide p3-Alcβ neutralizes brain Alzheimer's Aβ oligomers",

abstract = "Alcadeins are among the 90 known substrates for γ-secretase, the aspartyl proteinase complex that liberates the amyloid β (Aβ) peptide by intramembranous cleavage of the {\ss}-carboxy terminal fragment of the Alzheimer's amyloid precursor protein (APP). A new study by Hata et al. provides some surprising results regarding a potential role for alcadeins and their fragments in the prevention and/or treatment of the dementia of Alzheimer's disease (AD).",

keywords = "Alzheimer's disease, alcadein, amyloid, oligomer, positron emission tomography",

author = "Sam Gandy",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = jul,

doi = "10.1016/j.molmed.2023.04.007",

language = "English",

volume = "29",

pages = "487--488",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd.",

number = "7",

}

TY - JOUR

T1 - Systemically administered alcadein peptide p3-Alcβ neutralizes brain Alzheimer's Aβ oligomers

AU - Gandy, Sam

PY - 2023/7

Y1 - 2023/7

N2 - Alcadeins are among the 90 known substrates for γ-secretase, the aspartyl proteinase complex that liberates the amyloid β (Aβ) peptide by intramembranous cleavage of the ß-carboxy terminal fragment of the Alzheimer's amyloid precursor protein (APP). A new study by Hata et al. provides some surprising results regarding a potential role for alcadeins and their fragments in the prevention and/or treatment of the dementia of Alzheimer's disease (AD).

AB - Alcadeins are among the 90 known substrates for γ-secretase, the aspartyl proteinase complex that liberates the amyloid β (Aβ) peptide by intramembranous cleavage of the ß-carboxy terminal fragment of the Alzheimer's amyloid precursor protein (APP). A new study by Hata et al. provides some surprising results regarding a potential role for alcadeins and their fragments in the prevention and/or treatment of the dementia of Alzheimer's disease (AD).

KW - Alzheimer's disease

KW - alcadein

KW - amyloid

KW - oligomer

KW - positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=85158827582&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2023.04.007

DO - 10.1016/j.molmed.2023.04.007

M3 - Short survey

AN - SCOPUS:85158827582

SN - 1471-4914

VL - 29

SP - 487

EP - 488

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 7

ER -

Systemically administered alcadein peptide p3-Alcβ neutralizes brain Alzheimer's Aβ oligomers

Abstract

Keywords

Access to Document

Fingerprint

Cite this